Table 2.
Patient characteristics.
| Patient Characteristic | Male | Female | Total or p-Value |
|---|---|---|---|
| Total | 51 | 23 | 74 |
| Mean Age ± SD | 65 (45–87) | 66 (41–84) | 0.852 |
| Nodal Category (AJCC 8th) | |||
| N0 | 6 | 7 | 0.049 |
| N1/2 | 43 | 15 | |
| Tumor Category (AJCC 8th) | |||
| T2 | 7 | 1 | 0.201 |
| T3/4 | 39 | 21 | |
| PET Responders | |||
| No | 17 | 8 | 0.903 |
| Yes | 34 | 15 | |
| Progression-Free Survival | |||
| Yes | 15 | 6 | 0.694 |
| No | 34 | 17 | |
| Overall Survival (3 Yrs) | |||
| Yes | 20 | 10 | 0.831 |
| No | 29 | 13 | |
| Induction Chemotherapy | 51 | 23 | 74 |
| Capecitabine/Oxaliplatin | 0 | 1 | |
| Carboplatin/Irinotecan | 1 | 0 | |
| Carboplatin/Paclitaxel | 30 | 15 | |
| Cisplatin/Irinotecan | 18 | 5 | |
| Cisplatin/Irinotecan/Docetaxel | 1 | 1 | |
| Docetaxel/Irinotecan | 1 | 1 | |
| Change in Chemo Regimen Post-Induction PET/CT | |||
| Yes | 10 | 6 | 16 |
| No | 41 | 17 | 58 |
| SUVmax | 12.55 (10.01–15.64) |
12.51 (9.32–16.64) |
0.931 |